癸酸雌二醇

癸酸雌二醇
臨床資料
其他名稱	E2D、17β-癸酸雌二醇、雌二醇癸酸酯、17β-癸酸雌-1,3,5(10)-三烯-3,17β-二醇
給藥途徑	口服
藥物類別（英語：Drug class）	雌激素; 雌激素酯
識別資訊
	IUPAC命名法 [(8R,9S,13S,14S,17S)-3-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] decanoate; ;
CAS編號	61748-93-4
PubChem CID	66409;
ChemSpider	59783;
UNII	S4J8Z2L5LZ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID90210752 ;
化學資訊
化學式	C28H42O3
莫耳質量	426.64 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C;
	InChI InChI=1S/C28H42O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h12,14,19,23-26,29H,3-11,13,15-18H2,1-2H3/t23-,24-,25+,26+,28+/m1/s1; Key:YYFQNZXJGOTFRX-VMBLQBCYSA-N;

癸酸雌二醇（英語：Estradiol decanoate，簡稱E2D）或叫雌二醇癸酸酯或17β-癸酸雌二醇，是一種合成的甾體雌激素和雌激素酯，在1970年代後期被研究用於切除卵巢的女性的激素替代療法，但從未上市銷售。^[1]^[2]^[3]

已經在切除卵巢的婦女中研究了以0.25至0.5毫克/天的劑量口服油中的癸酸雌二醇，持續14天，發現產生的雌酮和雌二醇水平約為1:2 (0.5)至1:1.7 (0.6)。^[1]^[2]這與口服微粉化雌二醇相反，後者的雌酮與雌二醇之比約為5:1（與口服油中的癸酸雌二醇相比，比例相差8至10倍）。^[4]女性雌酮與雌二醇的正常比例在絕經前女性中約為1:2 (0.5)，在絕經後女性中約為2:1。^[4]因此，與口服微粉化雌二醇相比，口服油中的雌二醇癸酸酯可以提供更生理和更有利的雌酮和雌二醇水平。^[1]^[2]

口服癸酸雌二醇油中雌酮與雌二醇比率的優化可能與通過腸道淋巴系統的吸收有關，這使其可繞過肝臟中的首過代謝。^[5]這取決於癸酸雌二醇的脂肪酸癸酸酯，因此，不溶於油的口服癸酸雌二醇對齧齒動物的影響較小或沒有。^[5]通過淋巴系統吸收油中的口服雌二醇癸酸酯類似於油中的口服十一酸睪酮的情況。^[6]

參見

雌激素酯列表

參考資料

^ ^1.0 ^1.1 ^1.2 ^1.3 Kicovic PM, Luisi M, Franchi F, Alicicco E. Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women. Clin. Endocrinol. (Oxf). July 1977, 7 (1): 73–7. PMID 880735. S2CID 13639429. doi:10.1111/j.1365-2265.1977.tb02941.x.
^ ^2.0 ^2.1 ^2.2 ^2.3 Luisi M, Kicovic PM, Alicicco E, Franchi F. Effects of estradiol decanoate in ovariectomized women. J. Endocrinol. Invest. 1978, 1 (2): 101–6. PMID 755846. S2CID 38187367. doi:10.1007/BF03350355.
^ Ranjit Roy Chaudhury. Pharmacology of Estrogens. Elsevier Science & Technology Books. 1 January 1981: 36. ISBN 978-0-08-026869-9.
^ ^4.0 ^4.1 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2023-02-16]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始內容存檔 (PDF)於2016-08-22）.
^ ^5.0 ^5.1 de Visser J, van der Vies J. Oestrogenic activity of oestradiol-decanoate after oral administration to rodents. Acta Endocrinol. June 1977, 85 (2): 422–8. PMID 577331. doi:10.1530/acta.0.0850422.
^ Alexandre Hohl. Testosterone: From Basic to Clinical Aspects. Springer. 30 March 2017: 207–. ISBN 978-3-319-46086-4.

這是一篇關於類固醇的小作品。您可以透過編輯或修訂擴充其內容。

[pmid880735-1] 1.0 ^1.1 ^1.2 ^1.3 Kicovic PM, Luisi M, Franchi F, Alicicco E. Effects of orally administered oestradiol decanoate on plasma oestradiol, oestrone and gonadotrophin levels, vaginal cytology, cervical mucus and endometrium in ovariectomized women. Clin. Endocrinol. (Oxf). July 1977, 7 (1): 73–7. PMID 880735. S2CID 13639429. doi:10.1111/j.1365-2265.1977.tb02941.x.

[pmid755846-2] 2.0 ^2.1 ^2.2 ^2.3 Luisi M, Kicovic PM, Alicicco E, Franchi F. Effects of estradiol decanoate in ovariectomized women. J. Endocrinol. Invest. 1978, 1 (2): 101–6. PMID 755846. S2CID 38187367. doi:10.1007/BF03350355.

[Chaudhury1981-3] Ranjit Roy Chaudhury. Pharmacology of Estrogens. Elsevier Science & Technology Books. 1 January 1981: 36. ISBN 978-0-08-026869-9.

[pmid16112947-4] 4.0 ^4.1 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63 [2023-02-16]. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875. （原始內容存檔 (PDF)於2016-08-22）.

[pmid577331-5] 5.0 ^5.1 de Visser J, van der Vies J. Oestrogenic activity of oestradiol-decanoate after oral administration to rodents. Acta Endocrinol. June 1977, 85 (2): 422–8. PMID 577331. doi:10.1530/acta.0.0850422.

[Hohl2017-6] Alexandre Hohl. Testosterone: From Basic to Clinical Aspects. Springer. 30 March 2017: 207–. ISBN 978-3-319-46086-4.

[1]

[2]

[3]

[4]

[5]

[6]